Author:
Patel Asha R.,Turner Maria L.,Baird Kristin,Gea-Banacloche Juan,Mitchell Sandra,Pavletic Steven Z.,Wise Barbara,Cowen Edward W.
Subject
Transplantation,Hematology
Reference36 articles.
1. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors;Marr;Blood,2002
2. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality;Upton;Clin Infect Dis,2007
3. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis;Herbrecht;N Engl J Med,2002
4. Results of a randomized, double-blind trial of fluconazole (FLU) vs. voriconazole (VORI) for the prevention of invasive fungal infections (IFI) in 600 allogeneic blood and marrow transplant (BMT) patients;Wingard;ASH Annu Meet Abstr,2007
5. Vfend (Voriconazole, Oral and Intravenous Formulations), NDA 21-267, Briefing Document for FDA Antiviral Drugs Advisory Committee Meeting, 4 October 2001. Pfizer Inc. [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3792b2_01_Pfizer.pdf [Accessed 2007 October 18].
Cited by
44 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献